Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients

L. Ferrari, A. Martinetti, N. Zilembo, P. Pozzi, R. Buzzoni, I. La Torre, L. Gattinoni, L. Catena, M. Vitali, L. Celio, E. Seregni, E. Bombardieri, E. Bajetta

Research output: Contribution to journalArticle

Abstract

Insulin-like growth factors (IGFs) play a fundamental role in cancer development by acting in both an endocrinal and paracrinal manner, and hormone breast cancer treatments affect the IGF system by modifying circulating growth factor levels. We evaluated total IGF-1, IGF-2, IGF binding protein (IGFBP)-1 and IGFBP-3 in the blood of 34 postmenopausal advanced breast cancer patients (median age 63 years, range 41-85) treated with anastrozole, a non-steroidal structure aromatase inhibitor (NSS-AI). The plasma samples were obtained at baseline, and after 2, 4, 8 and 12 weeks of treatment. The IGFs were quantitated by means of sensitive radioimmunoassays (RIAs). IGF-1 significantly increased during anastrozole treatment (baseline versus 12 weeks, P=0.031), IGF-2 showed a trend towards an increase, and IGFBP-1 constantly but not significantly decreased; IGFBP-3 did not seem to be affected at all. The anastrozole-induced changes in IGFs and IGFBP-1 appeared to be different in the patients receiving a clinical benefit from those observed in non-responders. We have previously shown that letrozole (a different type of NSS-AI) modifies blood IGF-1 levels, and the results of this study of the biological effects of anastrozole on the components of the IGF system confirm our previous observations.

Original languageEnglish
Pages (from-to)411-418
Number of pages8
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume80
Issue number4-5
DOIs
Publication statusPublished - 2002

Fingerprint

Somatomedins
Breast Neoplasms
Insulin-Like Growth Factor Binding Protein 1
Aromatase Inhibitors
Insulin-Like Growth Factor Binding Protein 3
Therapeutics
letrozole
Blood
anastrozole
Insulin-Like Growth Factor Binding Proteins
Oncology
Radioimmunoassay
Intercellular Signaling Peptides and Proteins
Hormones
Plasmas

Keywords

  • Aromatase
  • Breast cancer
  • Growth factors
  • IGF-1
  • IGF-2
  • IGFBP-1
  • IGFBP-3
  • Postmenopause

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients. / Ferrari, L.; Martinetti, A.; Zilembo, N.; Pozzi, P.; Buzzoni, R.; La Torre, I.; Gattinoni, L.; Catena, L.; Vitali, M.; Celio, L.; Seregni, E.; Bombardieri, E.; Bajetta, E.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 80, No. 4-5, 2002, p. 411-418.

Research output: Contribution to journalArticle

Ferrari, L. ; Martinetti, A. ; Zilembo, N. ; Pozzi, P. ; Buzzoni, R. ; La Torre, I. ; Gattinoni, L. ; Catena, L. ; Vitali, M. ; Celio, L. ; Seregni, E. ; Bombardieri, E. ; Bajetta, E. / Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients. In: Journal of Steroid Biochemistry and Molecular Biology. 2002 ; Vol. 80, No. 4-5. pp. 411-418.
@article{3249d4d9455e4c308168e07084bff2f1,
title = "Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients",
abstract = "Insulin-like growth factors (IGFs) play a fundamental role in cancer development by acting in both an endocrinal and paracrinal manner, and hormone breast cancer treatments affect the IGF system by modifying circulating growth factor levels. We evaluated total IGF-1, IGF-2, IGF binding protein (IGFBP)-1 and IGFBP-3 in the blood of 34 postmenopausal advanced breast cancer patients (median age 63 years, range 41-85) treated with anastrozole, a non-steroidal structure aromatase inhibitor (NSS-AI). The plasma samples were obtained at baseline, and after 2, 4, 8 and 12 weeks of treatment. The IGFs were quantitated by means of sensitive radioimmunoassays (RIAs). IGF-1 significantly increased during anastrozole treatment (baseline versus 12 weeks, P=0.031), IGF-2 showed a trend towards an increase, and IGFBP-1 constantly but not significantly decreased; IGFBP-3 did not seem to be affected at all. The anastrozole-induced changes in IGFs and IGFBP-1 appeared to be different in the patients receiving a clinical benefit from those observed in non-responders. We have previously shown that letrozole (a different type of NSS-AI) modifies blood IGF-1 levels, and the results of this study of the biological effects of anastrozole on the components of the IGF system confirm our previous observations.",
keywords = "Aromatase, Breast cancer, Growth factors, IGF-1, IGF-2, IGFBP-1, IGFBP-3, Postmenopause",
author = "L. Ferrari and A. Martinetti and N. Zilembo and P. Pozzi and R. Buzzoni and {La Torre}, I. and L. Gattinoni and L. Catena and M. Vitali and L. Celio and E. Seregni and E. Bombardieri and E. Bajetta",
year = "2002",
doi = "10.1016/S0960-0760(02)00040-7",
language = "English",
volume = "80",
pages = "411--418",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "4-5",

}

TY - JOUR

T1 - Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients

AU - Ferrari, L.

AU - Martinetti, A.

AU - Zilembo, N.

AU - Pozzi, P.

AU - Buzzoni, R.

AU - La Torre, I.

AU - Gattinoni, L.

AU - Catena, L.

AU - Vitali, M.

AU - Celio, L.

AU - Seregni, E.

AU - Bombardieri, E.

AU - Bajetta, E.

PY - 2002

Y1 - 2002

N2 - Insulin-like growth factors (IGFs) play a fundamental role in cancer development by acting in both an endocrinal and paracrinal manner, and hormone breast cancer treatments affect the IGF system by modifying circulating growth factor levels. We evaluated total IGF-1, IGF-2, IGF binding protein (IGFBP)-1 and IGFBP-3 in the blood of 34 postmenopausal advanced breast cancer patients (median age 63 years, range 41-85) treated with anastrozole, a non-steroidal structure aromatase inhibitor (NSS-AI). The plasma samples were obtained at baseline, and after 2, 4, 8 and 12 weeks of treatment. The IGFs were quantitated by means of sensitive radioimmunoassays (RIAs). IGF-1 significantly increased during anastrozole treatment (baseline versus 12 weeks, P=0.031), IGF-2 showed a trend towards an increase, and IGFBP-1 constantly but not significantly decreased; IGFBP-3 did not seem to be affected at all. The anastrozole-induced changes in IGFs and IGFBP-1 appeared to be different in the patients receiving a clinical benefit from those observed in non-responders. We have previously shown that letrozole (a different type of NSS-AI) modifies blood IGF-1 levels, and the results of this study of the biological effects of anastrozole on the components of the IGF system confirm our previous observations.

AB - Insulin-like growth factors (IGFs) play a fundamental role in cancer development by acting in both an endocrinal and paracrinal manner, and hormone breast cancer treatments affect the IGF system by modifying circulating growth factor levels. We evaluated total IGF-1, IGF-2, IGF binding protein (IGFBP)-1 and IGFBP-3 in the blood of 34 postmenopausal advanced breast cancer patients (median age 63 years, range 41-85) treated with anastrozole, a non-steroidal structure aromatase inhibitor (NSS-AI). The plasma samples were obtained at baseline, and after 2, 4, 8 and 12 weeks of treatment. The IGFs were quantitated by means of sensitive radioimmunoassays (RIAs). IGF-1 significantly increased during anastrozole treatment (baseline versus 12 weeks, P=0.031), IGF-2 showed a trend towards an increase, and IGFBP-1 constantly but not significantly decreased; IGFBP-3 did not seem to be affected at all. The anastrozole-induced changes in IGFs and IGFBP-1 appeared to be different in the patients receiving a clinical benefit from those observed in non-responders. We have previously shown that letrozole (a different type of NSS-AI) modifies blood IGF-1 levels, and the results of this study of the biological effects of anastrozole on the components of the IGF system confirm our previous observations.

KW - Aromatase

KW - Breast cancer

KW - Growth factors

KW - IGF-1

KW - IGF-2

KW - IGFBP-1

KW - IGFBP-3

KW - Postmenopause

UR - http://www.scopus.com/inward/record.url?scp=18344366690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18344366690&partnerID=8YFLogxK

U2 - 10.1016/S0960-0760(02)00040-7

DO - 10.1016/S0960-0760(02)00040-7

M3 - Article

C2 - 11983488

AN - SCOPUS:18344366690

VL - 80

SP - 411

EP - 418

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 4-5

ER -